TrialAnnals of oncology : official journal of the European Society for Medical Oncology2023

Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma.

C E Sharon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.